Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$16.62 USD

16.62
845,519

+0.80 (5.06%)

Updated Sep 13, 2024 09:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.

STERIS (STE) AST Business Expands, New Offerings Aid Growth

STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan

Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region???s semiconductor manufacturing hub.

Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.

Are Medical Stocks Lagging Hims & Hers Health (HIMS) This Year?

Here is how Hims & Hers Health, Inc. (HIMS) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Carvana, Adobe, Amgen in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial

Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.

Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio

Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.

Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout

By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.

Omnicell (OMCL) Banks on Product Launches, Global Growth

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs

Thermo Fisher (TMO) has launched biobased solutions to help reduce the climate impact on the manufacturing of therapies.

Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab

Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.